MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the ...

A rare mutation that leads to high CREB3 activity is associated with a reduced risk of developing ALS and slower disease ...

Amylyx (AMLX) announced that the first participant has been dosed in LUMINA, the company’s Phase 1, multinational, randomized, double-blind, ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new ...

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves ...

The Ohio House Insurance Committee will hear proponent testimony on HB 24, a bill that would expand Medigap coverage to patients under 65, on Tuesday afternoon.

Schoox, a global leader in frontline workforce learning and skills development, has been selected by the ALS Association to ...

MediciNova (MNOV) announced enrollment of the first patient in the NIH-funded Expanded Access Program trial to evaluate MN-166 in patients with ...

Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on developing pioneering RNA-based medicines, today announced that the final, positive results from the Investigator-Initiated ...

Discover six life-changing books that offer unexpected insights. These titles delve into themes of personal growth, ...

Always eager to take on an opportunity to serve the public good, he was also on the programming committee for the continuing ...